Schizophrenia News and Research

Latest Schizophrenia News and Research

Viewpoints: Shortsighted fight against fund to prevent disease; strengthening regulators' control of premium increases

House Republicans are so bent on blocking any and all aspects of health care reform that they have passed a bill that would eliminate a farsighted program — the Prevention and Public Health Fund — intended to help states and communities prevent diseases. Eliminating the fund would save roughly $16 billion over the course of a decade. … The loss to states and local communities would be considerable.

27 Apr 2011

USPTO grants Cortex patent for CX1739 AMPAKINE molecule

Cortex Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent that protects its lead AMPAKINE® molecule, CX1739.

26 Apr 2011

Curemark CM-182 demonstrates positive results for schizophrenia in transgenic chakragati model of psychosis

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for schizophrenia in the transgenic chakragati (ckr) model of psychosis. The mouse model screening was performed by the Contract Research Organization, Cerca Insights.

25 Apr 2011

New findings can lead to better understanding of neurological development, cancer metastasis

By shedding new light on how cells migrate in the developing brain, researchers at Fred Hutchinson Cancer Research Center also may have found a new mechanism by which other types of cells, including cancer cells, travel within the body.

25 Apr 2011

State news: Calif. report faults screening of in-home care providers

Two of the state's largest private medical practices are in talks to merge into a giant doctor-run group that would care for nearly a million Massachusetts patients and significantly escalate the pace of health care consolidation throughout the state. Atrius Health, which runs the Harvard Vanguard system and four other doctors practices, is in advanced talks with Fallon Clinic, the Worcester-based medical group.

22 Apr 2011

Veterans with mental illness show increased rates of substance use disorders

A new study published in The American Journal on Addictions reveals that Veterans who suffer from mental health disorders also have high rates of substance use disorders.

21 Apr 2011

Neuralstem signs MoU with BaYi Brain Hospital for ischemic stroke program in China

Neuralstem, Inc. (NYSE Amex: CUR) announced it has signed a Memorandum of Understanding with BaYi Brain Hospital in Beijing, China.

21 Apr 2011

America’s best loved drugs: Report

According to the latest report from consulting firm IMS Health, Americans are consuming a lot of prescription drugs. And they seem especially fond of those to lower their cholesterol, relieve heartburn, aid in depressive disorders and lessen pain. Overall, however, their spending on such drugs is slowing.

20 Apr 2011

RCSI conducts study to examine psychiatric disorders in people with epilepsy

Researchers from the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital, Dublin, have conducted the first study of its kind to examine in detail, the basis of psychiatric disorders which occur in people with epilepsy.

20 Apr 2011

High rates of substance use disorders among veterans with mental illness

...

19 Apr 2011

Johnson & Johnson reports net sales of $16.2 billion for first quarter 2011

Johnson & Johnson today announced sales of $16.2 billion for the first quarter of 2011, an increase of 3.5% as compared to the first quarter of 2010.

19 Apr 2011

Intellectual disability may have genetic origin, but is not hereditary

Mutations in a group of genes associated with brain activity frequently cause intellectual disability, according to a study led by scientists affiliated with the University of Montreal and the research centre at the Centre hospitalier universitaire Sainte-Justine. Intellectual disability is a severe handicap that affects between one and two percent of children worldwide. It can often be attributed to genetic causes, but the specific genes involved were mostly unknown.

18 Apr 2011

Patients with schizophrenia can benefit from L-lysine treatment

Schizophrenia is a serious mental disorder that currently affects about one in every 200 people. Most patients find some relief from their symptoms by treatment with antipsychotics, however they may still suffer from cognitive and negative symptoms.

18 Apr 2011

Scientists identify filter neurons that can reduce 'brain clutter'

Until now, it has been assumed that people with diseases like ADHD, Tourette syndrome, obsessive compulsive disorder and schizophrenia - all of whom characteristically report symptoms of "brain clutter" - may suffer from anomalies in the brain's prefrontal cortex.

15 Apr 2011

Vanda initiates Fanapt Phase I study in patients with schizophrenia

Vanda Pharmaceuticals Inc. announced today that Novartis Pharmaceuticals Corporation, an affiliate of Vanda's sublicensor Novartis Pharma AG, has initiated a clinical study to evaluate the long-acting injectable formulation of Fanapt.

11 Apr 2011

Targacept's TC-5619 Phase 2 trial data in schizophrenia presented at ICOSR

Targacept, Inc. today announced the presentation of data from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia at the International Congress on Schizophrenia Research in Colorado Springs, Colorado.

8 Apr 2011